Here is a summary of the data for Utah : Share of all patients who take a GLP-1: 0.7% Share of patients with an obesity diagnosis who take a GLP-1: 4.8% Share of male patients with an obesity diagnosis who take a GLP-1: 4.4% Share of female patients with an obesity diagnosis who take a GLP-1: 5.1% Share of GLP-1 users that are female: 60.4% For reference, here are the statistics for the entire United States: Share of all patients who take a GLP-1: 1.0% Share of patients with an obesity diagnosis who take a GLP-1: 4.8% Share of male patients with an obesity diagnosis who take a GLP-1: 4.2% Share of female patients with an obesity diagnosis who take a GLP-1: 5.2% Share of GLP-1 users that are female: 64.7% For more information, a detailed methodology, and complete results, see U.S
Authoritative Sources ClinicalTrials.gov lists registered retatrutide studies and trial details: ClinicalTrials.gov retatrutide search
However, you might not be getting the full value of your supplement
Pawariya et al., 2024)
Purcell AE, Jeon OH, Zimmerman AW, Blue ME, Pevsner J
Furthermore, by evaluating their beneficial impacts on specific steroidogenic genes as well as histopathological assessment and lesion scoring of testicular, epididymal, seminal vesicular, and prostatic tissues, we intended to gain insight into the molecular mechanism by which LC and QT could alleviate ATZ toxicity in the testes
